AstraZeneca’s Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
But Lilly/Daiichi’s pending Effient has done the same thing, albeit with increased bleeding. Full PLATO data, to be released in August, will be scrutinized for safety.
You may also be interested in...
AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)
AstraZeneca's Ticagrelor Brilliant At ECS Congress; Will It Outshine Effient?
The comparator in AstraZeneca's PLATO trial for its antiplatelet candidate Brilinta (ticagrelor) was clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis' Plavix) but the real test for the product, should it reach the market, may be against Eli Lilly/Daiichi Sankyo's recently approved Effient (prasugrel)
Can The Medicines Company Rebound From A Phase III Blow?
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.